Welcome to our dedicated page for Synlogic SEC filings (Ticker: SYBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding lab notes. Synlogic’s 10-K alone blends metabolic pathways, clinical trial statistics, and liquidity warnings—all essential yet painfully dense. Stock Titan surfaces what matters the moment it hits EDGAR.
Need the "Synlogic quarterly earnings report 10-Q filing"? It’s here, auto-tagged, with AI-powered summaries that strip away jargon. Curious about "Synlogic insider trading Form 4 transactions" before the next catalyst read-out? Our dashboard delivers "Synlogic Form 4 insider transactions real-time", complete with context on each executive’s role in the synthetic-biotics pipeline.
Every filing type is covered and decoded:
- 10-K / 10-Q: Track R&D spend, cash runway, and pipeline updates—"Synlogic annual report 10-K simplified".
- 8-K: From FDA feedback to partnership news—"Synlogic 8-K material events explained".
- Form 4: Monitor "Synlogic executive stock transactions Form 4" to spot insider confidence.
- DEF 14A: Drill into "Synlogic proxy statement executive compensation" without scrolling hundreds of pages.
Our AI doesn’t just summarize; it answers the questions you type—"understanding Synlogic SEC documents with AI" or "Synlogic earnings report filing analysis"—so you can decide whether a new trial milestone truly shifts valuation. Real-time alerts, full historical archives, and plain-English explanations mean one thing: complex synthetic-biotics disclosures, finally clear.
Synlogic, Inc. (SYBX) filed its Q3 2025 report, highlighting a small operating footprint while pursuing strategic alternatives, including a possible merger or sale. The company recorded a net loss of $2.3 million for the quarter, driven largely by a $1.5 million loss from the change in fair value of purchase warrant liabilities.
Operating expenses were $1.0 million, reflecting minimal R&D activity after discontinuing the pivotal Synpheny‑3 trial in 2024 and completing a broad restructuring. Cash and cash equivalents were $15.6 million as of September 30, 2025, with management stating this is sufficient to fund operations for at least 12 months from the filing date. Stockholders’ equity stood at $10.3 million and purchase warrant liabilities at $5.3 million.
For the nine months, the company reported a net loss of $2.5 million, a significant improvement from the prior year due to restructuring completion and reduced operating costs. As of November 6, 2025, 11,698,919 shares were outstanding.
Synlogic, Inc. will hold its 2025 Annual Meeting on December 15, 2025 at 9:00 a.m. ET in a virtual-only format at www.virtualshareholdermeeting.com/SYBX2025. Stockholders can attend, submit questions, and vote online with their 16‑digit control number.
The agenda includes: (i) electing two Class I directors for three-year terms, (ii) an advisory vote on executive compensation, (iii) approval of the Synlogic, Inc. 2025 Equity Incentive Plan, and (iv) ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2025. The Board recommends voting FOR all proposals.
The record date is October 24, 2025, with 11,698,919 shares of common stock outstanding and entitled to vote. Voting is available via Internet, telephone, mail, or during the live webcast. Brokers may exercise discretion to vote only on the auditor ratification item (Proposal 4) absent instructions.
Synlogic (SYBX) insider transaction: Principal Executive and Financial Officer Mary Beth Dooley reported a sale of common stock. On October 29, 2025, she sold 157 shares at $1.81 per share.
The filing states the shares were sold to cover tax liabilities arising from a restricted stock award that vested on October 28, 2025 from a 2022 grant. Following the sale, she beneficially owned 12,744 shares directly. This appears to be routine tax withholding related to equity vesting rather than an open‑market discretionary sale.
Synlogic, Inc. filed an amended shelf registration statement on Form S-3/A (ticker SYBX) containing an exhibit index listing charter amendments, bylaws, stock certificate form, indentures, warrant/unit/rights forms, legal opinions, auditor consents, a trustee eligibility statement and a filing fee table. Several certificates of amendment are dated June 15, 2023 and September 27, 2023. The filing shows signatures by company officers and directors dated August 15, 2025.
Synlogic, Inc. (SYBX) filed a shelf registration on Form S-3 to offer up to $150,000,000 of securities, including common stock, preferred stock, debt and warrants. The company reported that it discontinued Synpheny-3, the pivotal Phase 3 study of its lead candidate labafenogene marselecobac (SYNB1934), in February 2024 after an internal review indicated the trial was unlikely to meet its primary endpoint, and stated the decision was not based on safety or tolerability concerns.
Management says its strategy now prioritizes strategic alternatives to enhance stockholder value, including a potential merger or sale, while earlier-stage programs remain in development, notably SYNB1353 which achieved proof of mechanism in a Phase 1 study. The prospectus notes the common stock trades on Nasdaq under SYBX, with 11,698,919 shares outstanding as of August 6, 2025 and a last reported sale price of $1.39 on August 7, 2025.
FAQ
What is the current stock price of Synlogic (SYBX)?
What is the market cap of Synlogic (SYBX)?
